Ascribe key facts
as of Oct 2026- Developer of crop protection products designed to protect crops from pests, fungi and other small orgasms.
- Ascribe is valued at approximately $48.0M as of Oct 2026 (last reported valuation).
- It has raised $20.7M; the latest was Later Stage VC ($15.0M) in Oct 2025.
- Notable investors include Creative Destruction Lab, US National Science Foundation, National Institutes of Health, Cultivation Capital, The Yield Lab — 16 tracked in total.
- Status: Privately Held (backing).
Ascribe's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Ascribe: the Monday email on marks, rounds and moves
Ascribe funding rounds
No funding rounds for Ascribe are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ascribe
16+Ascribe valuation
Ascribe's last reported valuation was $48 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Ascribe investors
16 investors are on record for Ascribe, including Creative Destruction Lab, US National Science Foundation, National Institutes of Health and Cultivation Capital.
About Ascribe
Developer of crop protection products designed to protect crops from pests, fungi and other small orgasms. The company's products are developed by researching the interaction of microbes and plants at the molecular level to identify the signaling molecules that activate a plant's natural immunity, enabling farmers to enhance the quality and productivity of crops.
- Sector
- Materials and Resources
- HQ
- Ithaca, NY, United States
- Founded
- 2017
- Employees
- 9
- Website
- ascribebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.